ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(2S,3R)-2-(2,4-ジフルオロフェニル)-3-(5-フルオロピリミジン-4-イル)-1-(1H-1,2,4-トリアゾール-1-イル)ブタン-2-オール

Voriconazole

HCID 71616
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
137234-62-9
標準SMILES
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
InChIKey
BCEHBSKCWLPMDN-MGPLVRAMSA-N
分子式
C16H14F3N5O
平均分子量
349.31 g/mol
単同位体質量
349.11504457

概要

Voriconazole is a triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. It has a role as a P450 inhibitor. It is a tertiary alcohol, a difluorobenzene, a member of pyrimidines, a conazole antifungal drug and a triazole antifungal drug.

名称と識別子

優先名称
Voriconazole
IUPAC
(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
現地名
(2S,3R)-2-(2,4-ジフルオロフェニル)-3-(5-フルオロピリミジン-4-イル)-1-(1H-1,2,4-トリアゾール-1-イル)ブタン-2-オール
英語名
Voriconazole-d3
分子式
C16H14F3N5O
分子量
349.31

名称と別名

Voriconazole137234-62-9Vfend(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-olUK-109496Voriconazol(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-olVoriconazolumUK-109,496UK 109496JFU09I87TRNSC-759888
名称をさらに表示
(2S,3R)-2-(2,4-ジフルオロフェニル)-3-(5-フルオロピリミジン-4-イル)-1-(1H-1,2,4-トリアゾール-1-イル)ブタン-2-オール3R)-2-(2VORICONAZOLE-D3(±)-VoriconazoleVoriconazole PI-6(2R,3R)-VoriconazoleFluconazole Intermediate 2Voriconazole Intermediate IIIntermediate 2 of voriconazole4-triazol-1-yl)-2-butanol (RaceMic Voriconazole)4-Difluorophenyl)-3-(5-fluoro-4-pyriMidinyl)-1-(1H-1
DTXSID5046485(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolCHEBI:10023(alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanolDTXCID3026485UK109496RefChem:56222UK109,496

物性

構造計算による物性補完中

XLogP
1.5
極性表面積
76.7 Ų
水素結合供与体数
1
水素結合受容体数
8
回転可能結合数
5
重原子数
25
形式電荷
0
複雑度
448

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use

PesticidesFungicides
LogP · 2 件

1

1.7

Solubility · 2 件

Low

9.78e-02 g/L

Human Drugs · 6 件

Breast Feeding; Lactation; Milk, Human; Antifungal Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point127 - 130 °C
Physical DescriptionSolid

物理化学的性質

沸点
508.6 · 508.6±60.0 °C(Predicted)
比重(密度)
1.42 · 1.42±0.1 g/cm3(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (99.2%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P264, P270, P273, P280, P301+P316, P318, P319, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 118 reports by companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationHazard Traits - Carcinogenicity
Hazard Classes and CategoriesAcute Tox. 3 (99.2%)

毒性情報

Hepatotoxicity · 1 件

Transient elevations in serum aminotransferase levels occur in 11% to 19% of patients on voriconazole. These elevations are usually asymptomatic and self-limited, but approximately 1% of patients require discontinuation of voriconazole because of ALT elevations. Clinically apparent hepatotoxicity is uncommon, but may be more frequent than with fluconazole and itraconazole. The injury arises within the first month of therapy and the pattern of serum enzyme elevations has been variable from cholestatic to hepatocellular. Several cases of acute liver failure attributed to voriconazole have been reported. Immunoallergic features and autoantibodies are uncommon. Recovery upon stopping therapy generally takes 6 to 10 weeks but, in some cases, the time to complete resolution may be prolonged.

Carcinogen Classification · 5 件

Voriconazole

Group 1: Carcinogenic to humans

Volume 137: (2026) Hydrochlorothiazide, Voriconazole, and Tacrolimus

2026 online

2024

Drug Induced Liver Injury

化学と産業

薬理情報

ATC Code · 4 件

J02AC03

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

J02AC03

Protein BindingVoriconazole is 58% bound to plasma proteins.
PharmacodynamicsVoriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth. It is known to cause hepatotoxic and photosensitivity reactions in some patients.
Mechanism of Action · 1 件

Voriconazole is used to treat fungal infections caused by a variety of organisms but including _Aspergillus spp._ and _Candida spp_. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens. Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host's immune system is able to clear the invading organism.

Biological Half-LifeVoriconazole follows non-linear kinetics and has a terminal half-life of elimination which is dose-dependent.
Metabolism/Metabolites · 2 件

Voriconazole undergoes extensive hepatic metabolism through cytochrome enzymes CYP2C9, CYP2C19, and CYP3A4. CYP2C19 mediates N-oxidation with an apparent Km of 14 μM and an apparent Vmax of 0.22 nmol/min/nmol CYP2C19. Voriconazole N-oxide is the major circulating metabolite, accounting for 72% of radiolabeled metabolites found. CYP3A4 contributes to N-oxidation with a Km of 16 μM and Vmax of 0.05 nmol/min/nmol CYP3A4 as well as 4-hydroxylation with a Km of 11 μM and a Vmax of 0.10 nmol/min/nmol CYP3A4. CYP3A5 and CYP3A7 provide minor contributions to N-oxidation and 4-hydroxylation. The N-oxide and 4-hydroxylated metabolites undergo glucuronidation and are excreted through the urine with other minor glucuronidated metabolites.

Voriconazole has known human metabolites that include Voriconazole N-Oxide and Hydroxymethyl Voriconazole.

関連反応

18 件
反応記録を作成
HRID 489474 の反応式
HRID 489474反応物として
HRID 1006649 の反応式
HRID 1006649反応物として
HRID 1051188 の反応式
HRID 1051188生成物として
HRID 1099517 の反応式
HRID 1099517反応物として
HRID 1099518 の反応式
HRID 1099518生成物として反応物として
HRID 1099519 の反応式
HRID 1099519反応物として
HRID 1099520 の反応式
HRID 1099520生成物として
HRID 1099521 の反応式
HRID 1099521生成物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
137234-62-9、188416-29-7
PubChem CID
71616
DTXSID
DTXSID201019420
ChEMBL
CHEMBL638
ChEBI
CHEBI:10023
UNII
JFU09I87TR、USG4B1CD29
EC Number
629-701-5、941-833-8
Nikkaji
J709.476K
貯蔵温度
2 · Storage temp. 2-8°C
酸解離定数(Pka)
11.54 · 11.54±0.29(Predicted)
外見
Solid
色
White to off-white
InChI
InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/s3
InChIKey
BCEHBSKCWLPMDN-NLBNCHMPNA-N
SMILES
C[C@@H]([C@@](CN1C=NC=N1)(C1C(F)=CC(F)=CC=1)O)C1C(F)=CN=CN=1 |&1:1,2,r|
· 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Voriconazole

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302
FDA Pharmacological Classification · 6 件

JFU09I87TR

VORICONAZOLE

Established Pharmacologic Class [EPC] - Azole Antifungal

Chemical Structure [CS] - Azoles

Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C19 Inhibitors

MeSH Pharmacological Classification · 3 件

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.

Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.

Absorption, Distribution and Excretion · 4 件

The oral bioavailability is estimated to be 96% in healthy adults. Population pharmacokinetic studies report a reduced bioavailability pediatric patients with a mean of 61.8% (range 44.6–64.5%) thought to be due to differences in first-pass metabolism or due to differences in diet. Of note, transplant patients also have reduced bioavailability but this is known to increase with time after transplantation and may be due in part to gastrointestinal upset from surgery and some transplant medications. Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. pH does not have an effect on absorption of voriconazole. Differences in Cmax and AUC have been observed between healthy adult males and females with Cmax increasing by 83% and AUC by 113% although this has not been observed to significantly impact medication safety profiles.

Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.

The estimated volume of distribution of voriconazole is 4.6 L/kg. Population pharmacokinetic studies estimate the median volume of distribution to be 77.6 L with the central compartment estimated at 1.07 L/kg Voriconazole is known to achieve therapeutic concentrations in many tissues including the brain, lungs, liver, spleen, kidneys, and heart.

The clearance of voriconazole is estimated to be a mean of 5.25-7 L/h in healthy adults for the linear portion of the drug's kinetics.

Cellular LocationsCytoplasm

用途と製造

UsesUse (kg; approx.) in Germany (2009): >100
Use ClassificationFungicides
応用分野 · 2 件

説明Voriconazole-d3 is an Ergosterol biosynthesis inhibitor and a labeled form of Voriconazole. This mono triazole antifungal agent inhibits the growth of Candida, Cryptococcus, and Aspergillus species. Studies suggest that Voriconazole-d3 can be synthesized by modifying the structure of fluconazole. This antifungal agent functions by inhibiting cytochrome P450 dependent 14-α-sterol demethylase, which is responsible for the biosynthesis of Ergosterol. Furthermore, Voriconazole-d3 inhibits fungal growth, cell wall thinning, and cell membrane degradation.

使用Voriconazole is a triazole antifungal agent used primarily in the treatment or prevention of aspergillosis and candidal infections. However, its therapy may cause transient, asymptomatic serum aminotransferase elevations, and it is also a well-known cause of acute drug-induced liver injury.